Researchers receive $5.8 m federal grant to build 3D liver model.
PITTSBURGH, Pa., September 24, 2014 -- NIH has awarded a $5.8 million, three-year grant to researchers at the University of Pittsburgh School of Medicine to develop a state-of-the-art, microfluidic 3D model system that mimics the structure and function of the liver to better predict organ physiology, assess drug toxicity and build disease models.
The funding supports the next phase of the NIH's Tissue Chip for Drug Screening program, which aims to improve ways of predicting drug safety and effectiveness.
Researchers from 11 institutions will collaborate over three years to refine existing 3-D human tissue chips and combine them into an integrated system that can mimic the complex functions of the human body.
"We are very enthusiastic about the potential of these microphysiology systems to serve as powerful platforms for studying human diseases and identifying human toxic liabilities," said Pitt project principal investigator D. Lansing Taylor.
"The development of tissue chips is a remarkable marriage of biology and engineering, and has the potential to transform preclinical testing of candidate treatments, providing valuable tools for biomedical research," said NIH Director Francis S. Collins.
The Pitt research team and collaborators are creating models of the functional unit of the liver, called the acinus, using human liver cells and eventually liver cells derived from precursor cells known as induced pluripotcnt stem cells, as well as three additional cell types.
The liver platform includes micro fluidic devices, human cells, engineered matrix materials, fluorescence-based biosensors for real-time physiological read-outs, and biochemical and mass spectrometry measurements to determine acute and chronic toxicity effects.
They also will build a "microphysiology database" to manage, analyze and model the data collected from the liver constructs.
With such a platform, biomedical scientists will be able to test treatment efficacy in conditions such as non-alcoholic fatty liver disease, liver cancer and breast cancer that has spread to the liver, as well as liver damage including immune-mediated toxicology and fibrosis.
Also, a team of institutions and investigators has been assembled to integrate the liver, kidney and gut models to recapitulate the organ system that is central to drug absorption and metabolism.
The integrated platform will involve the creation of a universal medium, the development of the proper "scaling" of the interacting organ constructs, physiologically relevant flow, incorporation of a micro-formulator to add factors from missing organs and micro-analyzers for monitoring parameters such as pH and oxygen.
Fifteen NIH Institutes and Centers are involved in the coordination of the tissue chip program.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Finance & Funding|
|Publication:||Stem Cell Business News|
|Date:||Oct 6, 2014|
|Previous Article:||NeoStem borrows $20 million.|
|Next Article:||Stemedica: patent for use of multiple stem cell lines to treat ischemic stroke.|